Revolutionising Thrombosis Treatment in ACS, SSP and AF: Bridging the Gaps With Next Generation Anticoagulation Strategies

Radcliffe Medical Education is hosting a CME-accredited* and ISCP endorsed symposium entitled 'Revolutionising Thrombosis Treatment in ACS, SSP and AF: Bridging the Gaps With Next Generation Anticoagulation Strategies' at the ESC Congress in Madrid (ES) on Friday 29 August 2025 at 10:00–10:45 CEST. The event will take place in room BAKU in Hall 4 at IFEMA Madrid.

Join Prof Carolyn Lam (Singapore, UK), Prof Davide Capodanno (Catania, IT), Dr Sneha Shah Jain (Stanford, US) and Prof Jeffrey Weitz (Hamilton, CA) as they examine the prevalence and challenges of stroke prevention in AF and ACS, review the guidelines for current treatments strategies, as well as exploring factor XI and innovations in antithrombotics, clinical trials and how these may shape clinical practice.  

Learning Objectives  After attending this symposium, physicians will be able to:

• Discuss the unmet needs in thrombosis management, MACE burden after ACS, stroke in AF and secondary stroke prevalence and consequence

• Evaluate the current standard of care for the treatment of ACS, SSP and AF and its limitations

• Review guidelines and critique current prescribing practices and the implications of inadequate treatment

• Explain the different strategies for targeting FXI and how FXI inhibition mechanisms differentiate from traditional anticoagulation therapies

• Identify emerging anticoagulant strategies and describe the efficacy and safety data from Phase 2 FXI inhibitor clinical trials as well as ongoing Phase 3 trials and potential place in therapy for ACS, AF and SSP

• Apply evidence-based anticoagulation strategies by optimising treatment decisions and addressing patient-specific risk factors

Programme 

Part 1 - Welcome – Prof Carolyn Lam

Part 2 - Stroke Prevention in AF and MACE after ACS: Prevalence and Challenges – Prof Davide Capodanno

Part 3 - Current Treatments in AF and ACS, Safety and Guidelines – Dr Sneha Shah Jain

Part 4 - Targeting Factor XI: Innovations in Anticoagulation – Dr Jeffrey Weitz

Part 5 - Shaping Clinical Practice and Clinical Trials – Prof Carolyn Lam

Part 6 - Audience Q&A and Closing Remarks – All Faculty

This satellite symposium is supported by an unrestricted educational grant from Bristol Myers Squibb and its Alliance partner Janssen Pharmaceuticals, Inc.  

*Revolutionising Thrombosis Treatment in ACS, SSP and AF: Bridging the Gaps With Next Generation Anticoagulation Strategies’ programme has been submitted to the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) seeking 1 CME credit, equating to 1 hour of effective education time.